HUSSMAN STRATEGIC ADVISORS, INC.

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1179475 ELLICOTT CITY, MD

Position in ACAD

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$3,739,680

-$186,690 QoQ

Shares Held

168,000

+14.3% QoQ

Ownership

0.098%

of shares outstanding

% of Portfolio

0.81%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2023

9 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

HUSSMAN STRATEGIC ADVISORS, INC. holds $44,137,764 across 23 Biotechnology names. ACAD ranks #2 (8.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	CORT	Corcept Therapeutics Inc	126,000	$5,079,060
2	ACAD	Acadia Pharmaceuticals Inc This page	168,000	$3,739,680
3	INVA	Innoviva, Inc.	147,000	$3,425,100
4	HALO	Halozyme Therapeutics, Inc.	52,500	$3,393,075
5	INCY	Incyte Corp	31,500	$2,964,780
6	STOK	Stoke Therapeutics, Inc.	84,000	$2,735,040
7	SEPN	Septerna, Inc.	105,000	$2,523,150
8	HRMY	Harmony Biosciences Holdings, Inc.	84,000	$2,352,840

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$3,739,680	168,000	+14.3%	Shares	Sole	2026-05-11
2025-12-31	$3,926,370	147,000	+16.7%	Shares	Sole	2026-02-02
2025-09-30	$2,688,840	126,000	+200.0%	Shares	Sole	2025-11-03
2024-06-30	$682,500	42,000	0.0%	Shares	Sole	2024-08-01
2024-03-31	$776,580	42,000	0.0%	Shares	Sole	2024-05-01
2023-12-31	$1,315,020	42,000	0.0%	Shares	Sole	2024-02-01
2023-09-30	$875,280	42,000	-32.3%	Shares	Sole	2023-11-08
2023-06-30	$1,484,900	62,000	-33.3%	Shares	Sole	2023-08-03
2023-03-31	$1,750,260	93,000	—	Shares	Sole	2023-05-05
No filing history on record for this holder in this stock.